Bionomics Limited reported QQ1 2024 results for the quarter ended 30 September 2024 with no revenue, continuing a pre-revenue burn typical of early-stage biotech companies. Total operating expenses were AUD 3.568 million, driven by Research and Development (AUD 1.901 million) and General and Administrative (AUD 1.667 million) costs, resulting in an EBITDA loss of AUD -3.402 million and an operating loss of AUD -3.568 million. Net income stood at AUD -0.805 million, while total other income contributed AUD 2.631 million, partially offsetting the operating loss. Diluted earnings per share were significantly negative at AUD -15.37, reflecting the high share base and non-cash expense items, compared with a basic EPS of AUD -0.61.